中国商报(记者 马嘉)近日,美国制药巨头辉瑞宣布终止最后一款口服GLP-1减肥药PF-06954522的研发。至此,辉瑞旗下已无口服GLP-1减肥药研发项目。在不到两年的时间里,辉瑞连续放弃三款口服GLP-1药物。业内人士认为,辉瑞退场或标志着口服减肥药研发具有技术壁垒,这一市场在很长一段时间内将由“先行者”掌控。未来,减肥药市场将是谁的天下?口服GLP-1药物研发屡战屡败近日,辉瑞在公布2025...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.